2027 ICD-10-CM Diagnosis Code C79.11Secondary malignant neoplasm of bladder

ICD-10-CM Codes›C00–D49›C76-C80›C79

ICD-10-CM C79.11
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

C79.11 is a billable ICD-10-CM diagnosis code for secondary malignant neoplasm of bladder. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 656 through 658, 686 through 688. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 25 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Secondary malignancies.

For Medicare Advantage risk adjustment, C79.11 maps to CMS-HCC Category 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid) under the V28 model, adding a risk factor of about 2.341 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
C79.11
Billable Status
Yes — Valid for Submission
Code Describes
Secondary malignant neoplasm of bladder
Short Description
Secondary malignant neoplasm of bladder
Same as the full description in the CMS dataset.
Parent Code
C79.1
Secondary malignant neoplasm of bladder and other and unspecified urinary organs

Code Classification

ChapterC00–D49Neoplasms
SectionC76-C80Malignant neoplasms of ill-defined, other secondary and unspecified sites
CategoryC79Secondary malignant neoplasm of other and unspecified sites
This CodeC79.11Secondary malignant neoplasm of bladder

Medicare Risk Adjustment (HCC)Billing

C79.11 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 18— Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid
Payment HCC · PY 2027 one of 26 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+2.341
community, non-dual, aged · ranges 1.110–2.537 across segments
Hierarchy
Superseded by HCC 17
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 8
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 8 · ESRD (V21): HCC 8 · ESRD (V24): HCC 8
ESRD V21 weights: 0.295 dialysis, 1.289–2.627 functioning graft · ESRD V24 weights: 0.353 dialysis, 1.571–3.226 functioning graft
Part D (RxHCC)
RxHCC 18 — Secondary Cancer of Lung, Liver, Brain, and Other Sites
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adenocarcinoma of urinary bladder
  • Malignant neoplasm involving urinary bladder by direct extension from endometrium
  • Malignant neoplasm involving urinary bladder by direct extension from fallopian tube
  • Malignant neoplasm involving urinary bladder by direct extension from ovary
  • Malignant neoplasm involving urinary bladder by direct extension from prostate
  • Malignant neoplasm involving urinary bladder by direct extension from uterine cervix
  • Malignant neoplasm involving urinary bladder by direct extension from uterus
  • Malignant neoplasm involving urinary bladder by direct extension from vagina
  • Malignant neoplasm of anterior wall of urinary bladder
  • Malignant neoplasm of dome of urinary bladder
  • Malignant neoplasm of lateral wall of urinary bladder
  • Malignant neoplasm of neck of urinary bladder
  • Malignant neoplasm of posterior wall of urinary bladder
  • Malignant neoplasm of trigone of urinary bladder
  • Malignant neoplasm of urachus
  • Malignant neoplasm of ureteral orifice
  • Mass of urinary bladder neck
  • Metastatic adenocarcinoma to urinary bladder
  • Metastatic carcinoma to urinary bladder
  • Metastatic malignant neoplasm to anterior wall of urinary bladder
  • Metastatic malignant neoplasm to apex of urinary bladder
  • Metastatic malignant neoplasm to dome of urinary bladder
  • Metastatic malignant neoplasm to lateral wall of urinary bladder
  • Metastatic malignant neoplasm to parietal peritoneum
  • Metastatic malignant neoplasm to posterior wall of urinary bladder
  • Metastatic malignant neoplasm to trigone of urinary bladder
  • Metastatic malignant neoplasm to urachus
  • Metastatic malignant neoplasm to ureter
  • Metastatic malignant neoplasm to ureteric orifice of urinary bladder
  • Metastatic malignant neoplasm to urinary bladder
  • Metastatic malignant neoplasm to urinary bladder neck
  • Metastatic transitional cell carcinoma to urinary bladder
  • Neoplasm of anterior wall of urinary bladder
  • Neoplasm of apex of urinary bladder
  • Neoplasm of dome of urinary bladder
  • Neoplasm of lateral wall of urinary bladder
  • Neoplasm of neck of urinary bladder
  • Neoplasm of posterior wall of urinary bladder
  • Neoplasm of trigone of urinary bladder
  • Neoplasm of urachus
  • Neoplasm of ureteric orifice of urinary bladder

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to C79.11: its own notes plus those printed at C79 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From C79 Secondary malignant neoplasm of other and unspecified sites applies to 25 codes
  • secondary carcinoid tumors (C7B.-)
  • secondary neuroendocrine tumors (C7B.-)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

  • lymph node metastases (C77.0)

Notes

General instructions on how these codes are used.

From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name C79.11, its category, or a range that includes it.

Applicable To 2

These notes mention C79.11.

  • Z85.8 Personal history of malignant neoplasms of other organs and systems
    Conditions classifiable to C00-C14, C40-C49, C69-C75, C7A.098, C76-C79 names C76-C79, which includes this code
  • Z85.89 Personal history of malignant neoplasm of other organs and systems
    Conditions classifiable to C7A.098, C76, C77-C79 names C77-C79, which includes this code

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO070
Secondary malignancies
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Metastatic Malignant Neoplasm in the Bladder

    the spread of a malignant neoplasm to the urinary bladder wall from an adjacent or distant anatomic site.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary		Malig.
Secondary		Ca
in situ		BenignUncertainUnspec.
bladder (urinary)C67.9C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › domeC67.1C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › neckC67.5C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › orificeC67.9C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › orifice › uretericC67.6C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › orifice › urethralC67.5C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › sphincterC67.8C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › trigoneC67.0C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › urachusC67.7C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › wallC67.9C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › wall › anteriorC67.3C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › wall › lateralC67.2C79.11D09.0D30.3D41.4D49.4
bladder (urinary) › wall › posteriorC67.4C79.11D09.0D30.3D41.4D49.4
urachusC67.7C79.11D09.0D30.3D41.4D49.4
ureter, ureteral › orifice (bladder)C67.6C79.11D09.0D30.3D41.4D49.4
ureter-bladder (junction)C67.6C79.11D09.0D30.3D41.4D49.4
urethra, urethral (gland) › orifice, internalC67.5C79.11D09.0D30.3D41.4D49.4

Patient EducationClinical

Bladder Cancer

The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C79.11 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
198.1 Sec malig neo urin NEC
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About C79.11Overview

What is the ICD-10 code for secondary malignant neoplasm of bladder?

The ICD-10-CM code for secondary malignant neoplasm of bladder is C79.11 (sometimes written as C7911). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is C79.11 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report secondary malignant neoplasm of bladder on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does C79.11 group to?

When secondary malignant neoplasm of bladder is the principal diagnosis on an inpatient stay, it groups to MS-DRG 656, 687, 658, 657, 686, 688, with relative weights from 0.7332 to 3.2782 depending on complications. Higher weights mean higher Medicare reimbursement.

Is C79.11 a CC or MCC?

CMS lists C79.11 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 25 closely related codes in its exclusion list.

Can C79.11 be reported with a code from C7B?

Not as a rule. The Excludes1 note at C79, which applies to C79.11, lists "secondary carcinoid tumors (C7B.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What HCC is C79.11?

C79.11 (secondary malignant neoplasm of bladder) maps to CMS-HCC Category 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid), commonly written as HCC 18, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 8 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 18.

Does C79.11 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C79.11 adds a risk adjustment factor of about 2.341 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 1.110 to 2.537 depending on the payment segment). A more severe related category (HCC 17) supersedes it when both are reported. See the full factor table on the HCC 18 category page.